193 related articles for article (PubMed ID: 22726543)
1. Discovery and development of second-generation proteasome inhibitors.
Kirk CJ
Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
[TBL] [Abstract][Full Text] [Related]
2. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Dou QP; Zonder JA
Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib for the treatment of non-Hodgkin's lymphoma.
Bose P; Batalo MS; Holkova B; Grant S
Expert Opin Pharmacother; 2014 Nov; 15(16):2443-59. PubMed ID: 25263936
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
Mitsiades CS
J Clin Oncol; 2015 Mar; 33(7):782-5. PubMed ID: 25605842
[No Abstract] [Full Text] [Related]
5. Carfilzomib: a novel second-generation proteasome inhibitor.
Khan ML; Stewart AK
Future Oncol; 2011 May; 7(5):607-12. PubMed ID: 21568676
[TBL] [Abstract][Full Text] [Related]
6. The future of proteasome inhibitors in relapsed/refractory multiple myeloma.
Orlowski RZ
Oncology (Williston Park); 2011 Nov; 25 Suppl 2(12 0 2):56-64. PubMed ID: 25188482
[TBL] [Abstract][Full Text] [Related]
7. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
Mitsiades CS; Hideshima T; Chauhan D; McMillin DW; Klippel S; Laubach JP; Munshi NC; Anderson KC; Richardson PG
Semin Hematol; 2009 Apr; 46(2):166-75. PubMed ID: 19389500
[TBL] [Abstract][Full Text] [Related]
8. Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.
Yang H; Landis-Piwowar KR; Chen D; Milacic V; Dou QP
Curr Protein Pept Sci; 2008 Jun; 9(3):227-39. PubMed ID: 18537678
[TBL] [Abstract][Full Text] [Related]
9. Fold up or perish: unfolded protein response and chemotherapy.
Strasser A; Puthalakath H
Cell Death Differ; 2008 Feb; 15(2):223-5. PubMed ID: 18049478
[No Abstract] [Full Text] [Related]
10. Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib.
Gelman JS; Sironi J; Berezniuk I; Dasgupta S; Castro LM; Gozzo FC; Ferro ES; Fricker LD
PLoS One; 2013; 8(1):e53263. PubMed ID: 23308178
[TBL] [Abstract][Full Text] [Related]
11. High-content microscopy reveals a morphological signature of bortezomib resistance.
Kelley ME; Berman AY; Stirling DR; Cimini BA; Han Y; Singh S; Carpenter AE; Kapoor TM; Way GP
Elife; 2023 Sep; 12():. PubMed ID: 37753907
[TBL] [Abstract][Full Text] [Related]
12. Site-Specific Proteasome Inhibitors.
Kisselev AF
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053202
[TBL] [Abstract][Full Text] [Related]
13. 3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies.
Lei M; Feng H; Wang C; Li H; Shi J; Wang J; Liu Z; Chen S; Hu S; Zhu Y
Bioorg Med Chem; 2016 Jun; 24(11):2576-2588. PubMed ID: 27117691
[TBL] [Abstract][Full Text] [Related]
14. Rational design of proteasome inhibitors based on the structure of the endogenous inhibitor PI31/Fub1.
Velez B; Razi A; Hubbard RD; Walsh R; Rawson S; Tian G; Finley D; Hanna J
Proc Natl Acad Sci U S A; 2023 Dec; 120(51):e2308417120. PubMed ID: 38091293
[TBL] [Abstract][Full Text] [Related]
15. Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.
Ferguson ID; Lin YT; Lam C; Shao H; Tharp KM; Hale M; Kasap C; Mariano MC; Kishishita A; Patiño Escobar B; Mandal K; Steri V; Wang D; Phojanakong P; Tuomivaara ST; Hann B; Driessen C; Van Ness B; Gestwicki JE; Wiita AP
Cell Chem Biol; 2022 Aug; 29(8):1288-1302.e7. PubMed ID: 35853457
[TBL] [Abstract][Full Text] [Related]
16. Oxidative stress and proteasome inhibitors in multiple myeloma.
Lipchick BC; Fink EE; Nikiforov MA
Pharmacol Res; 2016 Mar; 105():210-5. PubMed ID: 26827824
[TBL] [Abstract][Full Text] [Related]
17. Clinical development of novel proteasome inhibitors for cancer treatment.
Yang H; Zonder JA; Dou QP
Expert Opin Investig Drugs; 2009 Jul; 18(7):957-71. PubMed ID: 19505187
[TBL] [Abstract][Full Text] [Related]
18. Targeting myeloma metabolism: How abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors.
Zhou X; He R; Hu WX; Luo S; Hu J
Neoplasia; 2024 Apr; 50():100974. PubMed ID: 38364355
[TBL] [Abstract][Full Text] [Related]
19. Enzymatically Formed Peptide Assemblies Sequestrate Proteins and Relocate Inhibitors to Selectively Kill Cancer Cells.
He H; Liu S; Wu D; Xu B
Angew Chem Int Ed Engl; 2020 Sep; 59(38):16445-16450. PubMed ID: 32521103
[TBL] [Abstract][Full Text] [Related]
20. Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance.
Yang J; Yu YC; Wang ZX; Li QQ; Ding N; Leng XJ; Cai J; Zhang MY; Wang JJ; Zhou Y; Wei TH; Xue X; Dai WC; Sun SL; Yang Y; Li NG; Shi ZH
Eur J Med Chem; 2024 May; 271():116435. PubMed ID: 38648728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
